Resource implications of palliative chemotherapy for ovarian cancer

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 1000-1007

  Doyle, C ^a   Stockler, M ^a   Pintilie, M ^a   Panesar, P ^a   Warde, P ^a   Sturgeon, J ^a   Oza, A M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COST BENEFIT ANALYSIS; COST CONTROL; DATA ANALYSIS; FOLLOW UP; HEALTH CARE; HOME CARE; HUMAN; OVARY CANCER; PALLIATIVE THERAPY; PRIORITY JOURNAL; RECURRENT CANCER;

EID: 0031052353     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.1000     Document Type: Article

References (20)

1. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
2. Zanaboni F, Scarfone G, Presti M, et al: Salvage chemotherapy for ovarian cancer recurrence: Weekly cisplatin in combination with epirubicin or etoposide. Gynecol Oncol 43:24-28, 1991
3. Van der Burg MEL, Hoff AM, van Lent M, et al: Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. Eur J Cancer 27:248-250, 1991
4. Lorusso V, Catino A, Leone B, et al: Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: A pilot study. J Clin Oncol 11:1952-1956, 1993
5. Mc Guire WP, Rowinsky EK, Rosenshein NB, et al: Paclitaxel: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
6. Swenerton K, Eisenhauer E, ten Bokkel Huinink W, et al: Paclitaxel in relapsed ovarian cancer: High vs low dose and short vs long infusion: A European-Canadian study coordinated by the NCI Canada Trial Group. Proc Am Soc Clin Oncol 12:256, 1993 (abstr)
7. Trimble EL, Adams JD, Vena D, et al: Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11:2405-2410, 1993
8. Markman M, Hakes T, Reichman B, et al: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 10:243-248, 1992
9. Sutton GP, Blessing JA, Homesley HD, et al: Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 7:1672-1676, 1989
10. Rosen GF, Lurain JR, Newton M: Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy. Gynecol Oncol 27:173-179, 1987
11. Manetta A, MacNeill C, Lyter JA, et al: Hexamethylmelamine as a second-line agent in ovarian cancer. Gynecol Oncol 36:93-96, 1990
12. Vergote I, Himmelmann A, Frankendal B, et al: Hexamethylmelamine as second-line therapy in platinum-resistant ovarian cancer. Gynecol Oncol 47:282-286, 1992
13. Hull RD, Hirsh J, Sackett DL, et al: Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Can Med Assoc J 127:990-995, 1982
14. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. Aitkin M: A note on the regression analysis of censored data. Technometrics 23:161-163, 1981
16. Covens AL: Is paclitaxel cost-effective as first line therapy in advanced ovarian cancer? A medico-economic model. Curr Oncol 2:10-13, 1995 (suppl 1)
17. Richards MA, Braysher S, Gregory WM, et al: Advanced breast cancer: Use of resources and cost implications. Br J Cancer 67:856-860, 1993
18. Hurley SF, Huggins RM, Snyder RD, et al: The cost of breast cancer recurrences. Br J Cancer 65:449-455, 1992
19. de Koning HJ, van Ineveld BM, de Haes JCJM, et al: Advanced breast cancer and its prevention by screening. Br J Cancer 65:950-955, 1992
20. Jaakkimainen L, Goodwin PJ, Pater J, et al: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non small-cell lung cancer. J Clin Oncol 8:1301-1309, 1990